At the news
? BEARISHIMPACT 7/10 424B5 filed Apr 17, 2026 at 16:17 ET
Trevi Therapeutics priced a $150.8 million follow-on offering of 11.6 million shares at $13.00 per share, just one day after reporting earnings. The proceeds will fund clinical development of its lead candidate Haduvio through 2029, covering pivotal Phase 3 trials for IPF-related chronic cough and Phase 2b trials for non-IPF ILD and RCC indications. This offering follows a recent $150 million shelf registration and comes amid concerns about capital needs despite a preliminary cash balance of $171.8 million as of March 31, 2026.
- Offered 11,600,000 shares of common stock at $13.00 per share, raising $150.8 million in gross proceeds
- Offering priced one day after earnings release (April 17, 2026 8-K filing)
- Proceeds of approximately $141.1 million (after expenses) will fund clinical development of Haduvio through 2029
- Funds expected to cover Phase 3 trials for IPF-related chronic cough and Phase 2b trials for non-IPF ILD and RCC indications
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access